Psych Capital PLC - Drug Reform Group Representative Appointment

Psych Capital Plc

("Psych Capital" or the "Company")

Appointment of Conservative Drug Reform Policy Group Representative

Psych Capital Plc is pleased to announce the appointment of the Conservative Drug Reform Policy Group ("CDPRG") representative, Crispin Blunt, to its Medical Psychedelic Technical Advisory Board.

Since the Company's IPO, the board has been reviewing the regulatory landscape and investment opportunities in the UK, Europe and further afield, including drug development and patient delivery pathways. We have been actively working with the CDPRG, as part of our existing advisory agreement we have with them.

Their expertise in identifying regulatory barriers and opportunities, patient need, healthcare delivery frameworks, and political landscapes, have been instrumental as we actively assess a number of opportunities for strategic deployment of capital, leveraging our position as the first listed psychedelic company in London.

We want to be an active participant in shaping a delivery pathway for psychedelics to meet the significant unmet needs of patients in the UK and other markets, particularly in the context of an escalating mental health crisis.

William Potts, Chief Investment Officer, said: "Ahead of our next phase, we are delighted to add the CDPRG representative Crispin Blunt, a pioneering and leading healthcare politician leading the UK psychedelic health group, to our Psychedelic Medicines Technical Advisory Board, to augment our regulatory expertise, and to give us a seat at the table in shaping government / regulatory policy".

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Psych Capital Plc

Psych Capital Plc identifies, funds and aims to support the building of British and European companies across three core pillars: therapeutic treatments, drug development, and data/AI. Its mission is to support a new wave of innovators who are well positioned to challenge the status-quo and revolutionise how society deals with mental health conditions.

Through a network of analysts with deep industry knowledge and capital markets expertise, Psych Capital is focussed on developing a rigorously selected portfolio of industry leading companies at the intersection of psychedelic medicine and technology.

The Psych Platform is a business-to-business media and content platform for the psychedelic science and healthcare industry, and it operates the website, https://psych.global/. The Psych Platform is a global B2B resource for networking, intelligence and insights, servicing the industry through publications, newsletters and engaging events. The Psych Platform has amassed a significant global B2B audience, with over 20,000 subscribers to the platform.

As a business-to-business media and content platform, the Psych Platform also produces the PSYCH Symposium, a premium Live Event series.